





NEUROTRAIN

[MEST-CT-2005-020235] Early Stage Research Training funded through the European Union Research Programme [FP6]





Training and Understanding Neurodegenerative Diseases

Cognitive function is the most precious of all human attributes – its loss is considered as one of the most severe and dreadful handicaps for human life quality. The prevalence of neurodegenerative diseases is increasing in the European society and will get even more prevalent in our ageing population.

The focus of this Early Stage Research Training (EST) 'NEUROTRAIN' is to promote training possibilities and to improve our knowledge of neurodegeneration that will lead to prevention and therapy. LONDON (UK) LUND (Sweden) MUNICH (Germany) TÜBINGEN (Germany)



www.neurotrain.org

Partners

Stephen Minger (London, UK)
Nick Wood (London, UK)

Shomi Bhatthacharya (London, UK)
Olaf Riess (Tübingen, Germany)

Thomas Gasser (Tübingen, Germany)

Bernd Wissinger (Tübingen, Germany)

Thomas Wheeler-Schilling

(Tübingen, Germany)

Theo van Veen (Lund, Sweden)

Merab Kokaia (Lund, Sweden)

Tadeusz Wieloch (Lund, Sweden)

Marius Ueffing (Munich, Germany)

- **>>** Generation of dopaminergic neural precursor cells for Parkinson's disease.
- **>>** PINK 1 and molecular basis of cell degeneration in Parkinson's disease.
- **>>** Genetics and functional genomics of retinal degenerations.
- >> Investigation of disease mechanisms in Huntington's disease.
- **>>** Genetic and molecular basis of Parkinson's disease caused by LRRK2- mutations
- **>>** Genetic susceptibility factors in glaucoma.
- **>>** *Managing Coordinator.*
- **>>** Understanding the molecular basis of neuroprotection.
- **>>** Molecular basis of epilepsy and development of gene/cell based therapies
- **>>** Role of endoplasmic reticulum (ER) and unfolded protein response (EPR).
- >> Molecular studies in protein folding and pathological mechanisms of mitochondrial dysfunction.